EUVIMEDEUVIMED entdecken
Fallbericht

Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose

Evan Mak, Shannon Buck

Cutis · 2025

DOI: 10.12788/cutis.1228 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cutis, 2025. Verfasst von Evan Mak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Evan Mak is from the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Dr. Buck is from Landstuhl Regional Medical Center, Ge…. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Agents, Basal Cell Carcinoma, Nose Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesAntineoplastic AgentsBasal Cell CarcinomaNose NeoplasmsPyridinesSkin NeoplasmsAgedHumansMohs SurgeryTreatment Outcome

Substanzen

AnilidesAntineoplastic AgentsHhAntag691Pyridines

Autor:innen und Institutionen

  • Evan Mak is from the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Dr. Buck is from Landstuhl Regional Medical Center, Germany.

Zitieren

APA

Mak, E., & Buck, S. (2025). Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose. Cutis. https://doi.org/10.12788/cutis.1228

Vancouver

Mak E, Buck S. Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose. Cutis. 2025. doi:10.12788/cutis.1228

BibTeX
@article{Mak2025,
  author = {Mak, Evan and Buck, Shannon},
  title = {Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose},
  journal = {Cutis},
  year = {2025},
  doi = {10.12788/cutis.1228}
}
Kostenlos starten →